InvestSMART

Pro Medicus Limited (ASX: PME) - ETF Exposure

Current share price for PME : $161.310 3.02 (1.84%)+

Pro Medicus Limited (PME) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is involved in the development and supply of healthcare imaging software, Radiology Information System (RIS) software and services to hospitals, diagnostic imaging groups and other related health entities in Australia, North America and Europe.

PME General Information +

ASX Code PME
Website N/A
Industry/Sector Health Care Technology
Market Cap ($M) 16,852
PME Share Price $161.310
Day High $164.665
Day Low $159.710
Last Close $164.330
PME Share Price Movement $3.02 ( 1.84% )
Prices as at 16:40, 23 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to PME

As one of Australia's largest companies by market capitalisation, PME is held across 31 ETFs spanning strategies that include health care technology exposure . Its weighting in those funds means performance can have an outsized influence - when PME moves, funds like ATEC, XX20, AQLT, MVE and M1DS that hold it can move with it.

For more concentrated exposure, ETFs such as ATEC (BetaShares S&P/ASX Australian Technology ETF) allocate about 9.1% to PME , while the average exposure across all 31 ETFs that hold it is around 1.3% .

Top ETF holdings

Last updated: ETF data and holdings as at 23 September 2026

Own PME directly or through an ETF?

How does holding Pro Medicus Limited (PME) shares directly compare to ETFs that include it?

PME Direct
ATEC
ASX
XX20
ASX
AQLT
ASX
MVE
ASX
M1DS
CBOE
Holdings 1 company 46 holdings 29 holdings 46 holdings 53 holdings 54 holdings
PME Weight 100% 9.1% 8.1% 3.3% 2.8% 2.8%
Diversification Single Stock Broad Broad Broad Broad Broad
Annual Cost Brokerage only 0.48% p.a. 0.75% p.a. 0.35% p.a. 0.45% p.a. -
Approx. Yield 0.3% 1.96% 1.41% 4.13% 2.63% -
Star Ratings - starstarstarstar star starstarstarstar starstarstarstar star

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not PME's direct yield. Annual cost uses each ETF's MER.

PME Exposure on $10,000 investment

How a $10,000 investment in Pro Medicus Limited (PME) one week ago compares with ETFs that hold it.

Security Investment type Current price 7-day price movement Dollar change Value today
Pro Medicus Limited (PME) Direct share $161.310 -2.42% -$242 $9,758
BetaShares S&P/ASX Australian Technology ETF (ATEC) Equity - Australia Sectors $21.020 0.14% +$14 $10,014
First Sentier EX-20 Australian Share Active ETF (XX20) Equity - Australia Strategy $1.250 1.63% +$163 $10,163
BetaShares Australian Quality ETF (AQLT) Equity - Australia Strategy $34.890 1.01% +$101 $10,101
VanEck S&P/ASX MidCap ETF (MVE) Equity - Australia Small/Mid Cap $44.180 1.89% +$189 $10,189
Paradice Australian Mid Cap Fund Active ETF (M1DS) Equity - Australia Strategy $6.110 0% $0 $10,000

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Pro Medicus Limited (PME) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
HFResult 37¢ 100% 7 Sep 2026 29 Sep 2026 - - -
Result 32¢ 100% 26 Feb 2026 20 Mar 2026 - - -
HFResult 30¢ 100% 3 Sep 2025 25 Sep 2025 - - -

See all dividends from Pro Medicus Limited (PME) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Pro Medicus Limited (PME) price-sensitive announcements

PME - PME signs 7-year, A$25M contract with Valley Health
Pro Medicus Limited's subsidiary, Visage Imaging, Inc., has signed a 7-year, A$25M contrac
Pro Medicus Limited (PME)
21 Aug 2026 | 8:25 AM
PME - PME FY26 results presentation
For the financial year ending June 30, 2026, Pro Medicus Limited (ASX:PME), a leader in en
Pro Medicus Limited (PME)
18 Aug 2026 | 9:44 AM
PME - CEO Interview FY26 Results
Pro Medicus Limited's FY26 results reflect a year in line with expectations, highlighted b
Pro Medicus Limited (PME)
18 Aug 2026 | 9:36 AM
PME - PME Full Year Results
Pro Medicus Limited (PME) reported robust financial results for the fiscal year ending 30
Pro Medicus Limited (PME)
18 Aug 2026 | 9:32 AM

Pro Medicus Limited (PME) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Pro Medicus Limited (PME)
ORDINARY FULLY PAID
Health Care $16,852 Pro Medicus Ltd Appoints Non-Executive Director 23 Sep 2026 8:20AM $164.330 $161.310 fallen by 1.84%
Pro Medicus Limited (PME)
ORDINARY FULLY PAID
Health Care $16,852 Ceasing to be a substantial holder 7 Sep 2026 6:49PM $168.610 $161.310 fallen by 4.33%
Pro Medicus Limited (PME)
ORDINARY FULLY PAID
Health Care $16,852 PME signs 7-year, A$25M contract with Valley Health 21 Aug 2026 8:25AM $206.010 $161.310 fallen by 21.70%
Pro Medicus Limited (PME)
ORDINARY FULLY PAID
Health Care $16,852 Annual Report FY26 18 Aug 2026 10:05AM $180.190 $161.310 fallen by 10.48%
Pro Medicus Limited (PME)
ORDINARY FULLY PAID
Health Care $16,852 PME FY26 results presentation 18 Aug 2026 9:44AM $175.860 $161.310 fallen by 8.27%
Pro Medicus Limited (PME)
ORDINARY FULLY PAID
Health Care $16,852 CEO Interview FY26 Results 18 Aug 2026 9:36AM $175.860 $161.310 fallen by 8.27%

PME Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026F $113.01 $108.14 9.80% 263.74 54.00 0.19% 100.0%
2025F $102.88 $98.45 23.80% 289.70 49.00 0.17% 100.0%
2024A $83.21 $79.51 36.80% 116.74 40.00 0.43% 100.0%

PME Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 F 2026 F 2024 A 2025 F 2026 F 2024 A 2025 F 2026 F
4DMedical Limited (4DX) $2,400M 1.4982 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Artrya Limited (AYA) $624M -0.0450 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Pro Medicus Limited (PME) $17,168M 1.3034 -0.2811 0.2395 64.7989 90.1377 72.7188 0.42% 0.56% 0.70%

PME Directors

Name Position Start Date
Dr Sam Aaron Hupert Chief Executive Officer, Managing Director 1 Jan 1983
Mr Anthony Barry Hall Executive Director, Technology Director 1 Jan 1983
Mr Peter Terence Kempen Non-Executive Chairman, Non-Executive Director 12 Mar 2008
Ms Alice Joan Morrice Williams Non-Executive Director 1 Sep 2021
Ms Deena Robyn Shiff Non-Executive Director 1 Aug 2020
Mr Anthony James Glenning Non-Executive Director 1 May 2016
Dr Leigh Bernard Farrell Non-Executive Director 8 Sep 2017

Pro Medicus Limited (PME) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
26 Feb 2026 HALL, Anthony Buy Indirect Shares 8,146 $122.000 $993,812.000
25 Feb 2026 HALL, Anthony Buy Indirect Shares 9,000 $114.410 $1,029,690.000
24 Feb 2026 HUPERT, Sam Buy Indirect Shares 4,500 $108.720 $489,240.000

See all changes in directors' interest & trades for Pro Medicus Limited (PME) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

PME Management

Name Position
Danny English Company Secretary

PME Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Pro Medicus Limited (PME). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
24,196,660 (23.16%) Sam Aaron Hupert
24,174,166 (23.14%) Hall, Anthony Barry

PME Calendar of Events

Date Event
17 August 2027 Report (Annual)
17 August 2027 Report (Prelim)
11 February 2027 Report (Interim)
29 September 2026 Div Pay Date

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.